Categories AlphaGraphs, Earnings

Alexion beats earnings and sales estimates; raises guidance

Shares of biopharma company Alexion (ALXN) opened up 7% when market started today after it reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study.

The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue to $930.9 million. Earnings per share rose 48% to $1.11 and excluding items, the company’s earnings per share rose 22% during the quarter.

Net product sales of the key drug Soliris, which accounts for a bulk of the company’s revenue and is used to treat serious genetic-based blood condition, grew 2% during the quarter to $800.1 million.

Alexion has been working aggressively on rebuilding its pipeline. This is one of the reasons why it recently acquired Wilson Therapeutics based in Sweden. This deal, valued at $855 million, gives Alexion a greater control over the Wilson’s rare disease drug WTX101. Also, this new drug will reduce the company’s complete dependence on Soliris for generating revenue. The transaction is expected to close during the second quarter of this year.

The drugmaker also reported positive topline results for its Phase 3 study that is again used to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH).

The company also raised its guidance for revenue and adjusted EPS for the full year. Alexion now expects its revenue to be in the range of about $3.93 to 3.99 billion, up from the previous estimate of $3.85 to $3.95 billion and adjusted EPS to be about $6.75 to $6.90, up from the prior estimate of $6.60 to $6.80.

Today, apart from Alexion, two other drugmakers reported their results before the market opened. While AbbVie (ABBV) reported strong results and trades in the positive territory, Bristol-Myers Squibb (BMY) shares were down 1% in the morning session. Vertex Pharmaceuticals (VRTX) will announce its quarterly results after the market closes today.

Alexion earnings infographic
Alexion Pharmaceuticals Q1 2018 Earnings Infographic

Most Popular

Earnings Preview: What to look for when Broadcom (AVGO) reports Q1 results

Broadcom, Inc. (NASDAQ: AVGO) will be releasing its first-quarter results next week. Over the years, the company constantly broadened its portfolio beyond semiconductors to areas like enterprise software solutions, a

Here’s a look at Lowe’s (LOW) expectations for the near term and ahead

Shares of Lowe’s Companies, Inc. (NYSE: LOW) were up over 1% on Friday. The stock has gained 19% over the past three months. The home improvement retailer saw sales and

TJX Companies (TJX) Q4 2024 profit jumps on strong revenue growth

The TJX Companies, Inc. (NYSE: TJX) has reported a double-digit increase in net income for the fourth quarter of 2024 when the fashion retailer's net sales grew 13%. Fourth-quarter sales

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top